Drug Development
Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback
Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.
EvolutionaryScale Secures $142M for AI-Driven Drug Discovery
EvolutionaryScale, AI-driven drug discovery, $142M investment, drug development, pharmaceuticals
Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy
Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.
J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks
J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.
Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns
Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.
Bicycle Therapeutics Gears Up for Future Milestones with $555 Million Capital Infusion
Bicycle Therapeutics, funding, catalysts, biotechnology, drug development, clinical trials, investors, capital infusion, milestones.
Palisade Biotechnology’s Novel Ulcerative Colitis Treatment Shows Promising Results in Preclinical Studies
Palisade Biotechnology, ulcerative colitis, preclinical studies, nontoxic, mice, dogs, drug development, inflammatory bowel disease, treatment, prevention, symptoms
Otsuka Discontinues Alzheimer’s Agitation Drug Development Following Second Unsuccessful Trial
Otsuka, Alzheimer’s disease, agitation, drug development, clinical trials, failed trials, discontinuation
Biogen Expands Immunology Portfolio with $1.15 Billion Acquisition of HI-Bio
Biogen, HI-Bio, acquisition, immunology, $1.15 billion, expansion, therapeutics, drug development
AstraZeneca’s Ambitious Vision: Pursuing $80 Billion in Revenue and 20 New Drugs by 2030
AstraZeneca, revenue target, new drugs, 2030, growth strategy, pharmaceutical industry, healthcare innovation, biotechnology, drug development, market expansion.